S-23: research, sporting claims and risks

What S-23 is

S-23 is an investigational nonsteroidal androgen receptor modulator. It is distinct from S-4 despite the similar development-code style. One central research question was hormonal male contraception. That background matters when a sporting discussion focuses only on muscle outcomes and treats reproductive effects as an unrelated concern.

What the named research shows

Jones and colleagues, Endocrinology (2009; DOI 10.1210/en.2008-0674), investigated S-23 in male rats, including combinations used in a contraception model. Hormonal suppression and altered sperm production were central findings. These experiments were not human contraceptive or sports trials.

Animal contraception findings cannot establish reversible effects in humans.

Why it is discussed in sport

S-23 is sometimes portrayed as a stronger alternative within the SARM category. Such a ranking mixes receptor experiments, animal responses and anecdotal appearance changes. There is no common clinical comparison in the evidence reviewed here that supports it. A more useful sporting question is what has actually been measured in trained humans; the cited animal work does not supply that answer.

Risks and unresolved questions

Reproductive effects are a direct reason for caution, not a theoretical afterthought. Findings about recovery in rats cannot establish that fertility or hormone function will recover in a person. The evidence also does not define a safe exposure for healthy humans. FDA SARM warnings include liver injury. Unknown long-term outcomes and uncertain retail composition remain separate sources of uncertainty.

Reading product claims alongside evidence

A research publication and a retail product answer different questions. The image shows the actual source packaging for recognition. It does not confirm contents, purity, sterility or suitability. A particular batch would require traceable sampling, identity testing and appropriate analytical documentation. A percentage printed on a label alone does not replace that documentation.

This overview separates observed results from extrapolation to athletes. It provides no use protocol. Potential benefits are described as studied signals or as claims in sporting discussions; missing long-term data are not treated as reassurance. New publications can change the assessment. The draft still requires editorial review before publication.